Drug Eluting Balloons Catheters Global Market Report 2024

The drug eluting balloons catheters market size has grown rapidly in recent years. It will grow from $1.23 billion in 2023 to $1.43 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth observed in the historical period can be attributed to factors such as the increasing prevalence of respiratory disorders, the advantages offered over traditional inhalers, patient preferences for dry powder inhalers (DPIs), government initiatives for respiratory health, strategic collaborations and partnerships in the healthcare sector, advancements in drug formulations, and the rising geriatric population.

The drug eluting balloons catheters market size is expected to see rapid growth in the next few years. It will grow to $2.35 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The anticipated growth in the forecast period can be attributed to the ongoing increase in respiratory disorders, the expanding geriatric population, rising awareness and education regarding respiratory health, market expansion in emerging economies, the development of customized drug formulations, regulatory support and compliance, and innovations in packaging and design within the inhaler industry. Major trends expected in the forecast period include the emergence of smart inhalers and connectivity, a shift towards breath-actuated inhalers, a focus on meeting the needs of pediatric and geriatric patients, advancements in biologics delivery, and the development of environmentally friendly inhaler designs.

The anticipated rise in the prevalence of peripheral and cardiovascular diseases is set to drive the growth of the drug-eluting balloon catheter market in the future. Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and circulatory system, while peripheral artery disease (PAD) specifically involves narrowed arteries reducing blood flow to the arms or legs. Drug-eluting balloon catheters, a treatment for coronary artery disease (CAD), employ a semi-compliant angioplasty balloon coated with an anti-proliferative substance, providing an anti-restenotic effect upon entering the vessel. For example, in April 2023, the British Heart Foundation reported a rise in coronary heart disease deaths in the UK from 64,170 in 2020 to 65,579 in 2021. Additionally, HMP Global projected that peripheral arterial disease prevalence in the US would reach 23.8 million by 2030, up from 21 million in 2020. Hence, the growing prevalence of peripheral and cardiovascular diseases is a driving force behind the drug-eluting balloon catheter market.

The increasing demand for minimally invasive procedures is expected to further propel the growth of the drug-eluting balloon catheter market. Minimally invasive procedures involve surgical techniques with small incisions, resulting in reduced healing time, less pain, and lower infection risks. Drug-eluting balloons are crucial in these procedures, delivering medication directly to the treatment area to prevent restenosis and enhance the effectiveness of vascular interventions. For instance, Intuitive Surgical Inc. reported an 18% increase in surgical procedures using Vinci surgical systems from 1,594,000 in 2021 to 1,875,000 in 2022. Additionally, the American Society of Plastic Surgeons noted a rise in cosmetic minimally invasive procedures in the US to 23,672,269 in 2022. Therefore, the increasing demand for minimally invasive procedures is driving the growth of the drug-eluting balloon catheter market.

The negative impact of adverse effects associated with the treatment hindered the growth of the drug-eluting balloon catheter market during the historic period. While drug-eluting balloons present a promising treatment for coronary artery disease, careful consideration is necessary due to potential side effects. Medtronic PLC highlighted potential complications, including balloon rupture, detachment of components, failure to perform as intended, and failure to cross the lesion during peripheral balloon catheterization. Hence, adverse effects can negatively impact the growth of the drug-eluting balloon catheter market.

Major companies in the drug-eluting balloon catheter market are intensifying their focus on developing next-generation products with advanced technologies to gain a competitive edge. For instance, Medtronic PLC launched Prevail DCB in Europe in July 2021, the latest-generation drug-coated balloon catheter for treating coronary artery disease. Integrating paclitaxel, a quickly absorbed drug, and PowerTrac technology from Medtronic Resolute Onyx DES delivery system, Prevail DCB offers superior deliverability and pushing power in PCI procedures.

In June 2023, Translumina Therapeutics Company acquired Blue Medical Devices BV for an undisclosed amount. This strategic acquisition aimed to integrate Blue Medical's unique drug application technology into Translumina's product lines, expanding offerings in neurovascular and peripheral interventions and enhancing drug coating capabilities. Blue Medical Devices BV is a Netherlands-based medical device company specializing in producing drug-eluting balloon catheters.

Major companies operating in the drug eluting balloons catheters market report are Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips NV, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Mermaid Medical AS, Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Machine Solutions Inc., Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB.

North America was the largest region in the drug eluting balloons catheters market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug-eluting balloon catheter market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A drug-eluting balloon catheter is a medical device utilized in the treatment of coronary artery disease through percutaneous coronary intervention (PCI). It is a semi-compliant angioplasty balloon that is coated with an anti-proliferative drug. During inflation, the drug is released into the vessel wall, aiming to prevent restenosis and reduce the risk of late thrombosis without the need for implanting a permanent foreign object.

The main types of drug-eluting balloon catheters include those designed for coronary artery disease and peripheral vascular disease. Coronary artery disease drug-eluting balloon catheters deliver antiproliferative drugs directly to the vessel wall using a lipophilic matrix, eliminating the need for a permanent structure such as a metal prosthesis or persistent polymer. Various drugs such as paclitaxel and sirolimus are used, and the catheters are made from raw materials such as nylon, polyurethane, and others. They find applications in hospitals, clinics, ambulatory surgical centers, and catheterization laboratories.

The drug eluting balloons catherers market research report is one of a series of new reports that provides drug eluting balloons catherers market statistics, including drug eluting balloons catherers industry global market size, regional shares, competitors with a drug eluting balloons catherers market share, detailed drug eluting balloons catherers market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting balloons catherers industry. This drug eluting balloons catherers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug-eluting balloon catheter market consists of sales of everolimus and stellarex. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.